Trade PDS Biotechnology Corporation - PDSB CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading сonditions
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
PDS Biotechnology Corp ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 2.96 |
| Open* | 3.1 |
| 1-Year Change* | -52.6% |
| Day's Range* | 3.05 - 3.21 |
| 52 wk Range | 3.80-10.27 |
| Average Volume (10 days) | 684.12K |
| Average Volume (3 months) | 11.14M |
| Market Cap | 133.45M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 31.11M |
| Revenue | N/A |
| EPS | -1.70 |
| Dividend (Yield %) | N/A |
| Beta | 1.68 |
| Next Earnings Date | Mar 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 2.96 | 0.34 | 12.98% | 2.62 | 2.97 | 2.61 |
| Apr 19, 2024 | 2.62 | -0.16 | -5.76% | 2.78 | 2.88 | 2.57 |
| Apr 18, 2024 | 2.87 | 0.17 | 6.30% | 2.70 | 2.98 | 2.66 |
| Apr 17, 2024 | 2.69 | -0.10 | -3.58% | 2.79 | 2.79 | 2.65 |
| Apr 16, 2024 | 2.77 | -0.01 | -0.36% | 2.78 | 2.90 | 2.66 |
| Apr 15, 2024 | 2.79 | -0.38 | -11.99% | 3.17 | 3.19 | 2.78 |
| Apr 12, 2024 | 3.16 | -0.12 | -3.66% | 3.28 | 3.36 | 3.12 |
| Apr 11, 2024 | 3.34 | 0.19 | 6.03% | 3.15 | 3.38 | 3.15 |
| Apr 10, 2024 | 3.12 | 0.02 | 0.65% | 3.10 | 3.17 | 3.05 |
| Apr 9, 2024 | 3.25 | -0.03 | -0.91% | 3.28 | 3.29 | 3.07 |
| Apr 8, 2024 | 3.29 | 0.06 | 1.86% | 3.23 | 3.37 | 3.11 |
| Apr 5, 2024 | 3.20 | -0.01 | -0.31% | 3.21 | 3.35 | 3.15 |
| Apr 4, 2024 | 3.26 | -0.35 | -9.70% | 3.61 | 3.68 | 3.20 |
| Apr 3, 2024 | 3.65 | -0.08 | -2.14% | 3.73 | 3.74 | 3.59 |
| Apr 2, 2024 | 3.68 | -0.18 | -4.66% | 3.86 | 3.91 | 3.61 |
| Apr 1, 2024 | 3.98 | 0.00 | 0.00% | 3.98 | 4.00 | 3.76 |
| Mar 28, 2024 | 3.93 | 0.05 | 1.29% | 3.88 | 4.53 | 3.88 |
| Mar 27, 2024 | 3.80 | -0.19 | -4.76% | 3.99 | 4.28 | 3.59 |
| Mar 26, 2024 | 4.45 | -0.29 | -6.12% | 4.74 | 4.88 | 4.45 |
| Mar 25, 2024 | 4.70 | 0.18 | 3.98% | 4.52 | 4.79 | 4.52 |
PDS Biotechnology Corporation Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, May 13, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 PDS Biotechnology Corp Earnings Release Q1 2024 PDS Biotechnology Corp Earnings ReleaseForecast -Previous - |
| Friday, July 12, 2024 | ||
| Time (UTC) 13:00 | Country US
| Event PDS Biotechnology Corp Annual Shareholders Meeting PDS Biotechnology Corp Annual Shareholders MeetingForecast -Previous - |
| Monday, August 12, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2024 PDS Biotechnology Corp Earnings Release Q2 2024 PDS Biotechnology Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | ||||
| Total Operating Expense | 41.6724 | 21.4393 | 14.9024 | 7.70005 | 43.0966 |
| Selling/General/Admin. Expenses, Total | 12.2414 | 10.1848 | 6.96233 | 8.91149 | 15.0205 |
| Research & Development | 29.431 | 11.2545 | 7.92445 | 6.09958 | 16.0688 |
| Operating Income | -41.6724 | -21.4393 | -14.9024 | -7.70005 | -43.0966 |
| Interest Income (Expense), Net Non-Operating | -0.38134 | 0.00435 | 0.05501 | 0.31993 | -0.55338 |
| Other, Net | 0 | 0 | |||
| Net Income Before Taxes | -42.0538 | -21.435 | -14.8474 | -7.38012 | -43.6499 |
| Net Income After Taxes | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
| Net Income Before Extra. Items | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
| Net Income | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
| Total Adjustments to Net Income | |||||
| Income Available to Common Excl. Extra. Items | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
| Income Available to Common Incl. Extra. Items | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
| Diluted Net Income | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
| Diluted Weighted Average Shares | 28.5992 | 25.5971 | 16.745 | 4.86808 | 1.56211 |
| Diluted EPS Excluding Extraordinary Items | -1.42853 | -0.66095 | -0.88667 | -1.43765 | -26.1621 |
| Diluted Normalized EPS | -1.42853 | -0.66095 | -0.85692 | -2.41384 | -21.1658 |
| Total Extraordinary Items | 0 | ||||
| Unusual Expense (Income) | 0 | -7.31102 | 12.0073 | ||
| Depreciation / Amortization | 0.01561 | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 12.6962 | 9.42241 | 18.8214 | 7.2792 | 7.09265 |
| Selling/General/Admin. Expenses, Total | 4.69132 | 3.57873 | 2.66627 | 2.92621 | 3.33101 |
| Research & Development | 8.00485 | 5.84369 | 16.1551 | 4.35299 | 3.76165 |
| Operating Income | -12.6962 | -9.42241 | -18.8214 | -7.2792 | -7.09265 |
| Interest Income (Expense), Net Non-Operating | -0.24475 | -0.23751 | -0.14525 | 0.07455 | |
| Net Income Before Taxes | -12.9409 | -9.65992 | -19.1377 | -7.42445 | -7.01811 |
| Net Income After Taxes | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
| Net Income Before Extra. Items | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
| Net Income | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
| Income Available to Common Excl. Extra. Items | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
| Income Available to Common Incl. Extra. Items | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
| Diluted Net Income | -11.5349 | -9.65992 | -19.1377 | -7.42445 | -5.8192 |
| Diluted Weighted Average Shares | 30.8025 | 30.428 | 29.0379 | 28.4587 | 28.4516 |
| Diluted EPS Excluding Extraordinary Items | -0.37448 | -0.31747 | -0.65906 | -0.26089 | -0.20453 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.37448 | -0.31747 | -0.65906 | -0.26089 | -0.20453 |
| Other, Net | -0.31633 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 76.4804 | 66.8402 | 30.3372 | 14.4702 | 35.6511 |
| Cash and Short Term Investments | 73.8202 | 65.2426 | 28.8396 | 12.1617 | 34.6455 |
| Cash & Equivalents | 73.8202 | 65.2426 | 28.8396 | 12.1617 | 34.6455 |
| Prepaid Expenses | 2.66023 | 1.59757 | 1.49767 | 2.30846 | 1.00559 |
| Total Assets | 77.0079 | 67.1979 | 30.8904 | 14.4913 | 36.221 |
| Property/Plant/Equipment, Total - Net | 0.52753 | 0.3577 | 0.55315 | 0.02105 | 0.42695 |
| Property/Plant/Equipment, Total - Gross | 0.64295 | 0.47303 | 0.66313 | 0.11542 | 0.87862 |
| Accumulated Depreciation, Total | -0.11542 | -0.11533 | -0.10998 | -0.09437 | -0.45166 |
| Other Long Term Assets, Total | 0 | 0.14287 | |||
| Total Current Liabilities | 9.82104 | 3.75603 | 3.27045 | 2.79355 | 6.38175 |
| Accounts Payable | 1.21929 | 1.3094 | 1.41522 | 1.19772 | 0.39945 |
| Accrued Expenses | 8.54514 | 2.44663 | 1.85523 | 1.09764 | 0.38616 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.05661 | 0 | |||
| Other Current Liabilities, Total | 0 | 0.49819 | 5.59614 | ||
| Total Liabilities | 33.0059 | 3.98746 | 3.7608 | 2.79355 | 6.38175 |
| Total Long Term Debt | 23.1849 | 0 | 0 | 0 | 0 |
| Long Term Debt | 23.0208 | 0 | 0 | ||
| Total Equity | 44.002 | 63.2104 | 27.1296 | 11.6977 | 29.8392 |
| Common Stock | 0.00996 | 0.00939 | 0.00735 | 0.00174 | 0.01059 |
| Additional Paid-In Capital | 145.55 | 123.905 | 70.9073 | 40.6337 | 222.645 |
| Retained Earnings (Accumulated Deficit) | -101.558 | -60.7036 | -43.7851 | -28.9377 | -192.816 |
| Total Liabilities & Shareholders’ Equity | 77.0079 | 67.1979 | 30.8904 | 14.4913 | 36.221 |
| Total Common Shares Outstanding | 30.1703 | 28.4486 | 22.2616 | 5.28124 | 1.5725 |
| Preferred Stock - Non Redeemable, Net | 0 | ||||
| Other Liabilities, Total | 0 | 0.23143 | 0.49035 | 0 | |
| Capital Lease Obligations | 0.16401 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 56.8384 | 63.3509 | 67.9734 | 76.4804 | 74.4113 |
| Cash and Short Term Investments | 54.2514 | 60.625 | 65.1994 | 73.8202 | 71.6424 |
| Cash & Equivalents | 54.2514 | 60.625 | 65.1994 | 73.8202 | 71.6424 |
| Prepaid Expenses | 2.58703 | 2.72596 | 2.77399 | 2.66023 | 2.76891 |
| Total Assets | 57.1878 | 63.7542 | 68.4486 | 77.0079 | 74.8868 |
| Property/Plant/Equipment, Total - Net | 0.34941 | 0.4033 | 0.47526 | 0.52753 | 0.47542 |
| Total Current Liabilities | 9.15383 | 7.90419 | 4.12954 | 9.82104 | 4.84114 |
| Accounts Payable | 5.36656 | 4.41491 | 2.07206 | 1.21929 | 2.03739 |
| Accrued Expenses | 3.73273 | 3.43598 | 2.00537 | 8.54514 | 2.74248 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 32.704 | 31.3101 | 27.4377 | 33.0059 | 27.8279 |
| Total Long Term Debt | 23.5502 | 23.4059 | 23.3081 | 23.1849 | 22.9868 |
| Other Liabilities, Total | 0 | 0 | |||
| Total Equity | 24.4838 | 32.4442 | 41.0109 | 44.002 | 47.0588 |
| Common Stock | 0.01023 | 0.01019 | 0.01014 | 0.00996 | 0.00939 |
| Additional Paid-In Capital | 158.076 | 155.187 | 152.219 | 145.55 | 129.47 |
| Retained Earnings (Accumulated Deficit) | -133.602 | -122.753 | -111.218 | -101.558 | -82.4207 |
| Total Liabilities & Shareholders’ Equity | 57.1878 | 63.7542 | 68.4486 | 77.0079 | 74.8868 |
| Total Common Shares Outstanding | 31.0078 | 30.8682 | 30.7236 | 30.1703 | 28.4587 |
| Current Port. of LT Debt/Capital Leases | 0.05454 | 0.05331 | 0.05211 | 0.05661 | 0.06127 |
| Long Term Debt | 23.4128 | 23.2544 | 23.1428 | 23.0208 | 22.9097 |
| Capital Lease Obligations | 0.1374 | 0.15151 | 0.16529 | 0.16401 | 0.07713 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -40.8549 | -16.9185 | -14.8474 | -6.99861 | -40.868 |
| Cash From Operating Activities | -25.7097 | -12.4861 | -13.1491 | -18.0735 | -33.1533 |
| Cash From Operating Activities | 0.04908 | 0.00536 | 0.01561 | 0.09841 | 0.17435 |
| Non-Cash Items | 10.6211 | 4.35124 | 0.61297 | -6.22017 | 10.9689 |
| Cash Interest Paid | 0.85222 | 0 | 1.05117 | ||
| Changes in Working Capital | 4.47498 | 0.07582 | 1.06967 | -4.5716 | -3.4285 |
| Cash From Investing Activities | 0 | 29.3815 | 0 | ||
| Capital Expenditures | 0 | ||||
| Cash From Financing Activities | 34.2872 | 48.8891 | 29.827 | 0.75 | -20.2688 |
| Financing Cash Flow Items | -0.72029 | -0.99 | |||
| Issuance (Retirement) of Stock, Net | 10.0075 | 48.8891 | 29.827 | 0.75 | 0.7212 |
| Issuance (Retirement) of Debt, Net | 25 | 0 | -20 | ||
| Net Change in Cash | 8.57754 | 36.4031 | 16.6778 | 12.058 | -53.4221 |
| Deferred Taxes | 0 | -0.38151 | |||
| Cash Taxes Paid | 0 | ||||
| Other Investing Cash Flow Items, Total | 0 | 29.3815 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.65992 | -40.8549 | -21.7172 | -14.2927 | -8.47352 |
| Cash From Operating Activities | -13.1886 | -25.7097 | -18.1808 | -12.2879 | -6.36901 |
| Cash From Operating Activities | 0.01411 | 0.04908 | 0.0375 | 0.00009 | 0.00009 |
| Non-Cash Items | 2.26257 | 10.6211 | 4.07542 | 2.59809 | 1.18923 |
| Changes in Working Capital | -5.8054 | 4.47498 | -0.57652 | -0.59332 | 0.9152 |
| Cash From Financing Activities | 4.56786 | 34.2872 | 24.5806 | 0.02992 | 0.00749 |
| Issuance (Retirement) of Stock, Net | 4.58852 | 10.0075 | 0.02992 | 0.02992 | 0.00749 |
| Net Change in Cash | -8.62078 | 8.57754 | 6.39982 | -12.2579 | -6.36152 |
| Cash Interest Paid | 0.96685 | 0.85222 | 0.0625 | ||
| Financing Cash Flow Items | -0.72029 | -0.44933 | |||
| Issuance (Retirement) of Debt, Net | -0.02067 | 25 | 25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
PDS Biotechnology Corporation Company profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.| Industry: | Bio Therapeutic Drugs |
303A College Road East
PRINCETON
NEW JERSEY 08540
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com